Pharmacogenetics of Psychotropic Drugs
Herausgeber: Lerer, Bernard
Pharmacogenetics of Psychotropic Drugs
Herausgeber: Lerer, Bernard
- Broschiertes Buch
- Merkliste
- Auf die Merkliste
- Bewerten Bewerten
- Teilen
- Produkt teilen
- Produkterinnerung
- Produkterinnerung
This 2002 text defines the field of pharmacogenetics as it applies to psychotropic drugs, for clinicians and researchers.
Andere Kunden interessierten sich auch für
![Ghodse's Drugs and Addictive Behaviour]( "Ghodse's Drugs and Addictive Behaviour")
Hamid GhodseGhodse's Drugs and Addictive Behaviour159,99 €![Physical Illness and Schizophrenia]( "Physical Illness and Schizophrenia")
Stefan LeuchtPhysical Illness and Schizophrenia64,99 €![Society and Psychosis]( "Society and Psychosis")
Craig Morgan / Kwame McKenzie / Paul Fearon (eds.)Society and Psychosis69,99 €![Insight in Psychiatry]( "Insight in Psychiatry")
Ivana MarkováInsight in Psychiatry56,99 €![Outcome Neurodevelop Genetic Disord]( "Outcome Neurodevelop Genetic Disord")
Patricia Howlin / Orlee Udwin (eds.)Outcome Neurodevelop Genetic Disord113,99 €![Anxiety Disorders]( "Anxiety Disorders")
Anxiety Disorders141,99 €![Workplace-Based Assessments in Psychiatric Training]( "Workplace-Based Assessments in Psychiatric Training")
Workplace-Based Assessments in Psychiatric Training61,99 €-
-
-
This 2002 text defines the field of pharmacogenetics as it applies to psychotropic drugs, for clinicians and researchers.
Produktdetails
- Produktdetails
- Verlag: Cambridge University Press
- Seitenzahl: 460
- Erscheinungstermin: 21. Januar 2011
- Englisch
- Abmessung: 244mm x 170mm x 25mm
- Gewicht: 788g
- ISBN-13: 9780521189613
- ISBN-10: 0521189616
- Artikelnr.: 32733116
- Verlag: Cambridge University Press
- Seitenzahl: 460
- Erscheinungstermin: 21. Januar 2011
- Englisch
- Abmessung: 244mm x 170mm x 25mm
- Gewicht: 788g
- ISBN-13: 9780521189613
- ISBN-10: 0521189616
- Artikelnr.: 32733116
Part I. Introduction: 1. Genes and psychopharmacology: exploring the
interface Bernard Lerer; Part II. Clinical Background and Research Design:
2. From pharmacogenetics to pharmacogenomics of psychotropic drug response
Anil K. Malhotra; 3. Neuropsychopharmacology: the interface between genes
and psychiatric nosology Thomas A. Ban; 4. Methodological issues in
psychopharmacogenetics Sheldon H. Preskorn; 5. Statistical approaches in
psychopharmacogenetics Fabio Macciardi; Part III. Molecular Background: 6.
The psychopharmacogenetic-neurodevelopmental interface in serotonergic gene
pathways K. Peter Lesch, Jens Benninghoff and Angelika Schmitt; 7. RNA
processing regulation and interindividual variation Colleen M. Niswender
and Linda K. Hutchinson; Part IV. Pharmacokinetics: 8. Pharmacogenetics of
psychotropic drug metabolism Vural Ozdemir, Angela D. M. Kashuba, Vincenzo
S. Basile and James L . Kennedy; 9. Pharmacogenetics of chiral psychotropic
drugs Pierre Baumann and Chin B. Eap; Part V. Specific Psychotropic Drugs
and Disorders: 10. Clozapine response and genetic variation in
neurotransmitter receptor targets David A. Collier, Maria J. Arranz, Sarah
Osborne, Katherine J. Aitchison, Janet Munro, Dalu Mancama and Robert W.
Kerwin; 11. Genetic factors underlying drug-induced tardive dyskinesia
Ronnen H. Segman and Bernard Lerer; 12. Functional gene-linked polymorphic
regions in pharmacogenetics Marco Catalano; 13. Alternative phenotypes and
the pharmacogenetics of mood and anxiety disorders Emanuela Mundo and James
L. Kennedy; 14. Pharmacogenetics of anxiolytic drugs and the
GABA-benzodiazepine receptor complex Smita A. Pandit, Spilios V.
Argyropoulous, Patrick G. Kehoe and David J. Nutt; 15. Genetic factors and
long-term prophylaxis in bipolar disorder Martin Alda; 16. Genetic
influences on responsiveness to anticonvulsant drugs Thomas N. Ferraro; 17.
Apolipoprotein E as a marker in the treatment of Alzheimer's disease Keith
Schappert, Pierre Sevigny and Judes Poirier; 18. Genetic variation and drug
dependence risk factors Joel Gelernter and Henry Kranzler; Part VI.
Pharmacogenetics and Brain Imaging: 19. Brain imaging and pharmacogenetics
in Alzheimer's disease and schizophrenia Steven G. Potkin, James L. Kennedy
and Vincenzo S. Basile; Part VII. Industry perspectives: 20.
Pharmacogenetics in psychotropic drug discovery and development William Z.
Potter, AnnCatherine Van Lone and Larry Altstiel; 21. High-throughput
single nucleotide polymorphism genotyping Anne Shalom and Ariel Darvasi;
Index.
interface Bernard Lerer; Part II. Clinical Background and Research Design:
2. From pharmacogenetics to pharmacogenomics of psychotropic drug response
Anil K. Malhotra; 3. Neuropsychopharmacology: the interface between genes
and psychiatric nosology Thomas A. Ban; 4. Methodological issues in
psychopharmacogenetics Sheldon H. Preskorn; 5. Statistical approaches in
psychopharmacogenetics Fabio Macciardi; Part III. Molecular Background: 6.
The psychopharmacogenetic-neurodevelopmental interface in serotonergic gene
pathways K. Peter Lesch, Jens Benninghoff and Angelika Schmitt; 7. RNA
processing regulation and interindividual variation Colleen M. Niswender
and Linda K. Hutchinson; Part IV. Pharmacokinetics: 8. Pharmacogenetics of
psychotropic drug metabolism Vural Ozdemir, Angela D. M. Kashuba, Vincenzo
S. Basile and James L . Kennedy; 9. Pharmacogenetics of chiral psychotropic
drugs Pierre Baumann and Chin B. Eap; Part V. Specific Psychotropic Drugs
and Disorders: 10. Clozapine response and genetic variation in
neurotransmitter receptor targets David A. Collier, Maria J. Arranz, Sarah
Osborne, Katherine J. Aitchison, Janet Munro, Dalu Mancama and Robert W.
Kerwin; 11. Genetic factors underlying drug-induced tardive dyskinesia
Ronnen H. Segman and Bernard Lerer; 12. Functional gene-linked polymorphic
regions in pharmacogenetics Marco Catalano; 13. Alternative phenotypes and
the pharmacogenetics of mood and anxiety disorders Emanuela Mundo and James
L. Kennedy; 14. Pharmacogenetics of anxiolytic drugs and the
GABA-benzodiazepine receptor complex Smita A. Pandit, Spilios V.
Argyropoulous, Patrick G. Kehoe and David J. Nutt; 15. Genetic factors and
long-term prophylaxis in bipolar disorder Martin Alda; 16. Genetic
influences on responsiveness to anticonvulsant drugs Thomas N. Ferraro; 17.
Apolipoprotein E as a marker in the treatment of Alzheimer's disease Keith
Schappert, Pierre Sevigny and Judes Poirier; 18. Genetic variation and drug
dependence risk factors Joel Gelernter and Henry Kranzler; Part VI.
Pharmacogenetics and Brain Imaging: 19. Brain imaging and pharmacogenetics
in Alzheimer's disease and schizophrenia Steven G. Potkin, James L. Kennedy
and Vincenzo S. Basile; Part VII. Industry perspectives: 20.
Pharmacogenetics in psychotropic drug discovery and development William Z.
Potter, AnnCatherine Van Lone and Larry Altstiel; 21. High-throughput
single nucleotide polymorphism genotyping Anne Shalom and Ariel Darvasi;
Index.
Part I. Introduction: 1. Genes and psychopharmacology: exploring the
interface Bernard Lerer; Part II. Clinical Background and Research Design:
2. From pharmacogenetics to pharmacogenomics of psychotropic drug response
Anil K. Malhotra; 3. Neuropsychopharmacology: the interface between genes
and psychiatric nosology Thomas A. Ban; 4. Methodological issues in
psychopharmacogenetics Sheldon H. Preskorn; 5. Statistical approaches in
psychopharmacogenetics Fabio Macciardi; Part III. Molecular Background: 6.
The psychopharmacogenetic-neurodevelopmental interface in serotonergic gene
pathways K. Peter Lesch, Jens Benninghoff and Angelika Schmitt; 7. RNA
processing regulation and interindividual variation Colleen M. Niswender
and Linda K. Hutchinson; Part IV. Pharmacokinetics: 8. Pharmacogenetics of
psychotropic drug metabolism Vural Ozdemir, Angela D. M. Kashuba, Vincenzo
S. Basile and James L . Kennedy; 9. Pharmacogenetics of chiral psychotropic
drugs Pierre Baumann and Chin B. Eap; Part V. Specific Psychotropic Drugs
and Disorders: 10. Clozapine response and genetic variation in
neurotransmitter receptor targets David A. Collier, Maria J. Arranz, Sarah
Osborne, Katherine J. Aitchison, Janet Munro, Dalu Mancama and Robert W.
Kerwin; 11. Genetic factors underlying drug-induced tardive dyskinesia
Ronnen H. Segman and Bernard Lerer; 12. Functional gene-linked polymorphic
regions in pharmacogenetics Marco Catalano; 13. Alternative phenotypes and
the pharmacogenetics of mood and anxiety disorders Emanuela Mundo and James
L. Kennedy; 14. Pharmacogenetics of anxiolytic drugs and the
GABA-benzodiazepine receptor complex Smita A. Pandit, Spilios V.
Argyropoulous, Patrick G. Kehoe and David J. Nutt; 15. Genetic factors and
long-term prophylaxis in bipolar disorder Martin Alda; 16. Genetic
influences on responsiveness to anticonvulsant drugs Thomas N. Ferraro; 17.
Apolipoprotein E as a marker in the treatment of Alzheimer's disease Keith
Schappert, Pierre Sevigny and Judes Poirier; 18. Genetic variation and drug
dependence risk factors Joel Gelernter and Henry Kranzler; Part VI.
Pharmacogenetics and Brain Imaging: 19. Brain imaging and pharmacogenetics
in Alzheimer's disease and schizophrenia Steven G. Potkin, James L. Kennedy
and Vincenzo S. Basile; Part VII. Industry perspectives: 20.
Pharmacogenetics in psychotropic drug discovery and development William Z.
Potter, AnnCatherine Van Lone and Larry Altstiel; 21. High-throughput
single nucleotide polymorphism genotyping Anne Shalom and Ariel Darvasi;
Index.
interface Bernard Lerer; Part II. Clinical Background and Research Design:
2. From pharmacogenetics to pharmacogenomics of psychotropic drug response
Anil K. Malhotra; 3. Neuropsychopharmacology: the interface between genes
and psychiatric nosology Thomas A. Ban; 4. Methodological issues in
psychopharmacogenetics Sheldon H. Preskorn; 5. Statistical approaches in
psychopharmacogenetics Fabio Macciardi; Part III. Molecular Background: 6.
The psychopharmacogenetic-neurodevelopmental interface in serotonergic gene
pathways K. Peter Lesch, Jens Benninghoff and Angelika Schmitt; 7. RNA
processing regulation and interindividual variation Colleen M. Niswender
and Linda K. Hutchinson; Part IV. Pharmacokinetics: 8. Pharmacogenetics of
psychotropic drug metabolism Vural Ozdemir, Angela D. M. Kashuba, Vincenzo
S. Basile and James L . Kennedy; 9. Pharmacogenetics of chiral psychotropic
drugs Pierre Baumann and Chin B. Eap; Part V. Specific Psychotropic Drugs
and Disorders: 10. Clozapine response and genetic variation in
neurotransmitter receptor targets David A. Collier, Maria J. Arranz, Sarah
Osborne, Katherine J. Aitchison, Janet Munro, Dalu Mancama and Robert W.
Kerwin; 11. Genetic factors underlying drug-induced tardive dyskinesia
Ronnen H. Segman and Bernard Lerer; 12. Functional gene-linked polymorphic
regions in pharmacogenetics Marco Catalano; 13. Alternative phenotypes and
the pharmacogenetics of mood and anxiety disorders Emanuela Mundo and James
L. Kennedy; 14. Pharmacogenetics of anxiolytic drugs and the
GABA-benzodiazepine receptor complex Smita A. Pandit, Spilios V.
Argyropoulous, Patrick G. Kehoe and David J. Nutt; 15. Genetic factors and
long-term prophylaxis in bipolar disorder Martin Alda; 16. Genetic
influences on responsiveness to anticonvulsant drugs Thomas N. Ferraro; 17.
Apolipoprotein E as a marker in the treatment of Alzheimer's disease Keith
Schappert, Pierre Sevigny and Judes Poirier; 18. Genetic variation and drug
dependence risk factors Joel Gelernter and Henry Kranzler; Part VI.
Pharmacogenetics and Brain Imaging: 19. Brain imaging and pharmacogenetics
in Alzheimer's disease and schizophrenia Steven G. Potkin, James L. Kennedy
and Vincenzo S. Basile; Part VII. Industry perspectives: 20.
Pharmacogenetics in psychotropic drug discovery and development William Z.
Potter, AnnCatherine Van Lone and Larry Altstiel; 21. High-throughput
single nucleotide polymorphism genotyping Anne Shalom and Ariel Darvasi;
Index.